Self-management of immunomodulatory drug treatment in multiple myeloma patients.
adherence
immunomodulatory drugs
multiple myeloma
questionnaire
self-management
side effects
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
07
10
2019
revised:
10
07
2020
accepted:
14
10
2020
pubmed:
8
11
2020
medline:
30
9
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
Immunomodulatory drugs (IMIDs: thalidomide, lenalidomide and pomalidomide) are widely used in patients with multiple myeloma (MM). The aim of our study was to validate a questionnaire to evaluate the self-capacity of MM patients to manage IMID treatment including side effects. We used a method adapted from the recommendations of the European Organisation for Research and Treatment of Cancer (EORTC) to validate a French questionnaire for patients with MM treated with IMIDs. The face validity was evaluated in 15 patients and the construct validity in 56 patients. For discriminant validity, two groups were constituted by gender and depending on whether they had a previous IMID treatment. The median questionnaire score was 11.33/16 (IQR 9.75-12.08) with a minimum of 5.2 and a maximum of 14.75. For discriminant validity, a statistically significant difference was observed for patient capacity to contact healthcare professionals in specific situations and drug intake in case of swallowing disorder. Convergent validity showed an acceptable reliability for the scores of the different questions. The questionnaire has shown to be a valid tool for the assessment of the adherence and side-effect management skills for MM patients with IMID treatment.
Substances chimiques
Pharmaceutical Preparations
0
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Langues
eng
Pagination
e13356Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Agresti, A. (2012). Analysis of ordinal categorical data, 2nd ed. Wiley.
Ahmadidarrehsima, S., Bidmeshki, E. A., Rahnama, M., Babaei, K., Afshari, M., & Khandani, B. K. (2019). The effect of self-management education by the teach-back method on uncertainty of patients with breast cancer: A quasi-experimental study. Journal of Cancer Education, 35(2), 366-372. https://doi.org/10.1007/s13187-019-1474-5
Arber, A., Odelius, A., Williams, P., Lemanska, A., & Faithfull, S. (2017). Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study. European Journal of Cancer Care, 26(2), e12413-https://doi.org/10.1111/ecc.12413
Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197-198. https://doi.org/10.1001/jama.2017.7156
Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., …, Schrag, D. (2016). Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. Journal of Clinical Oncology, 34(6), 557-565. https://doi.org/10.1200/JCO.2015.63.0830
Baudot, A., Oriol, M., Tinquaut, F., Moine, V., Moriceau, G., Muron, T., & Bourmaud, A. (2016). Validation of a questionnaire assessing patients’ adherence and skill level of management for oral capecitabine treatment. Bulletin Du Cancer, 103(3), 241-251. https://doi.org/10.1016/j.bulcan.2016.01.010
Berry, D. L., Blonquist, T. M., Hong, F., Halpenny, B., & Partridge, A. H. (2015). Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. Patient Prefer Adherence, 9, 1587-1592. https://doi.org/10.2147/PPA.S91534
Blimark, C. H., Turesson, I., Genell, A., Ahlberg, L., Björkstrand, B. O., Carlson, K., …, Kristinsson, S. Y. (2018). Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica, 103(3), 506-513. https://doi.org/10.3324/haematol.2017.178103
Caracuel, F., Banos, U., Herrera, M. D., Ramirez, G., & Munoz, N. (2014). Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. International Journal of Clinical Pharmacy, 36(2), 287-290. https://doi.org/10.1007/s11096-014-9915-z
Claros, M. P., Messa, C. V. M., & Garcia-Perdomo, H. A. (2019). Adherence to oral pharmacological treatment in cancer patients: Systematic review. Oncology Reviews, 13(1), https://doi.org/10.4081/oncol.2019.402
Cortina, J. (1993). What is coefficient alpha? An examination of theory and applications. Journal of Applied Psychology, 78(1), 98-104. https://doi.org/10.1037/0021-9010.78.1.98
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., &, Fitzmaurice, C. (2018). Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol, 4(9), 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128
Dimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., …, Weber, D. M. (2009). Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia, 23(11), 2147-2152. https://doi.org/10.1038/leu.2009.147
Favier-Archinard, C., Leguelinel-Blache, G., Cousin, C., Gillet, C., Bourquard, P., Dubois, F., …, Favier, M. (2018). Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Final validation. Bulletin Du Cancer, 105(12), 1157-1172. https://doi.org/10.1016/j.bulcan.2018.09.006
Food and Drug Administration. (2009). Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Food and Drug Administration Retrieved from https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf
Johnson, C., Aaronson, A., Blazeby, J., Bottomley, A., Fayers, P., Koller, M., …, Young, T. (2011). EORTC quality of Life Group guidelines for developing questionnaire modules (pp. 47).
Kolovos, S., Nador, G., Kishore, B., Streetly, M., Rabin, N. K., Chantry, A. D., …, Pinedo-Villanueva, R. (2019). Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of Bone Oncology, 17, 100243. https://doi.org/10.1016/j.jbo.2019.100243
Kumar, S. K., Vij, R., Noga, S. J., Berg, D., Brent, L., Dollar, L., & Chari, A. (2017). Treating multiple myeloma patients with oral therapies. Clinical Lymphoma Myeloma and Leukemia, 17(5), 243-251. https://doi.org/10.1016/j.clml.2017.02.024
Mateos, M.-V., Ocio, E. M., Paiva, B., Rosiñol, L., Martínez-López, J., Bladé, J., …, San Miguel, J. F. (2015). Treatment for patients with newly diagnosed multiple myeloma in 2015. [Research Support, Non-U.S. Gov't Review]. Blood Reviews, 29(6), 387-403. https://doi.org/10.1016/j.blre.2015.06.001
Monterosso, L., Taylor, K., Platt, V., Lobb, E., Musiello, T., Bulsara, C., …, Krishnasamy, M. (2018). Living With multiple myeloma: A focus group study of unmet needs and preferences for survivorship care. Journal of Patient Experience, 5(1), 6-15. https://doi.org/10.1177/2374373517715011
Moreau, P., Dimopoulos, M. A., Richardson, P. G., Siegel, D. S., Cavo, M., Corradini, P., &, San-Miguel, J. (2017). Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. European Journal of Haematology, 99(3), 199-206. https://doi.org/10.1111/ejh.12903
Palumbo, A., Mateos, M. V., Bringhen, S., & San Miguel, J. F. (2011). Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? [Review]. Blood Reviews, 25(4), 181-191. https://doi.org/10.1016/j.blre.2011.03.005
Quach, H., Fernyhough, L., Henderson, R., Corbett, G., Baker, B., Browett, P., …, Miles Prince, H. (2017). Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: Final analysis of the phase II RevLite study. British Journal of Haematology, 177(3), 441-448. https://doi.org/10.1111/bjh.14562
Ribed, A., Romero-Jimenez, R. M., Escudero-Vilaplana, V., Iglesias-Peinado, I., Herranz-Alonso, A., Codina, C., & Sanjurjo-Saez, M. (2016). Pharmaceutical care program for onco-hematologic outpatients: Safety, efficiency and patient satisfaction. International Journal of Clinical Pharmacy, 38(2), 280-288. https://doi.org/10.1007/s11096-015-0235-8
Song, X., Wilson, K. L., Kagan, J., & Panjabi, S. (2019). Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis. Therapeutic Advances in Hematology, 10, 204062071983902. https://doi.org/10.1177/2040620719839025
Taber, K. S. (2018). The use of Cronbach's alpha when developing and reporting research instruments in science education. Research in Science Education, 48(6), 1273-1296. https://doi.org/10.1007/s11165-016-9602-2
Wang, Y., Huang, H., Zeng, Y., Wu, J., Wang, R., Ren, B., & Xu, F. (2013). Pharmacist-led medication education in cancer pain control: a multicentre randomized controlled study in Guangzhou, China. Journal of International Medical Research, 41(5), 1462-1472. https://doi.org/10.1177/0300060513491170
Wang, Y., Wu, H., & Xu, F. (2015). Impact of clinical pharmacy services on KAP and QOL in cancer patients: A single-center experience. BioMed Research International, 2015, 1-8. https://doi.org/10.1155/2015/502431
Wong, S. F., Bounthavong, M., Nguyen, C., Bechtoldt, K., & Hernandez, E. (2014). Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. American Journal of Health System Pharmacy, 71(11), 960-965. https://doi.org/10.2146/ajhp130278